Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background: Active surveillance (AS) is a standard approach to treat low and intermediate risk prostate cancer. For AS, disease progression is monitored. AS uses biopsies, prostate specific antigen (PSA) blood tests, and other tools. Researchers want to see if multiparametric magnetic resonance imaging (mpMRI) can help improve AS. Objective: To see if mpMRI can improve how people are monitored during AS. Eligibility: Men age 18 and older who have been diagnosed with prostate cancer within the last 2 years. Design: Participants will undergo AS. Their PSA level will be checked once a year via blood test. They will have a digital rectal exam once a year. Participants will have biopsies every 2-3 years. Needles will be put into different parts of the prostate. The needles are guided by ultrasound imaging. Participants will also have targeted biopsies with mpMRI and MRI guided fusion (MRI-US fusion). MRI-US fusion combines previous MRI images with live ultrasound images. For MRIs, participants will lie on their stomach on the scanner table. A coil may be placed in the rectum. Participants will have a physical exam and medical record review at least every 3 years. Their weight and vital signs will be checked. They will give data about their daily activities, side effects, and symptoms. Every 2-3 years, participants will fill out surveys about their prostate health and quality of life. Participants may give blood, urine, prostate secretion, and saliva samples. The samples will be used for research. Participation will last for as long as the participant does not need actual treatment for his prostate cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyźni w wieku 18 lat i starsi, u których zdiagnozowano raka prostaty w ciągu ostatnich 2 lat.
- •Rak prostaty potwierdzony w badaniu histologicznym, z niskim lub umiarkowanym stopniem zaawansowania (Gleason 7 lub niższy).
- •Potwierdzony przez patologa NCI (lub możliwość pobrania nowej próbki).
- •Stan kliniczny raka: wczesne stadium.
- •Zrozumienie i chęć podpisania zgody na udział w badaniu oraz na ścisłą obserwację raka prostaty.
- •Udział w równoległym protokole badawczym dotyczącym opieki nad pacjentem z rakiem prostaty i pozyskiwania tkanek.
✗ Disqualifies
- •Rak prostaty, który rozprzestrzenił się na inne części ciała lub jest zaawansowany miejscowo.
- •Wcześniejsza radioterapia w okolicy miednicy.
- •Przeciwwskazania do biopsji prostaty, takie jak niezdiagnozowane problemy z krzepnięciem krwi, ciężkie osłabienie odporności, zaawansowane hemoroidy lub wcześniejsze operacje w obrębie miednicy utrudniające badanie.
- •Przeciwwskazania do rezonansu magnetycznego prostaty, w tym alergia na środki kontrastowe lub problemy z nerkami.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 1, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
National Institutes of Health Clinical Center
Bethesda, United States
Trial contact
Karen K Holcomb
Peter A Pinto, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.